ASV Insights highlights recent deals in women’s health and sexual health. This week we review the reproductive health and obstetrics landscape following CooperCompanies’ acquisition of Cook Medical’s OBGYN product line.
CooperCompanies, the parent company of CooperSurgical, bought a suite of OBGYN products from Cook Medical to expand their Medical Device portfolio. The deal was valued at $300M USD. The purchase included a fetal heart rate monitor and a handful of minimally invasive devices designed to help with labor preparation, postpartum healing and blood flow monitoring.
CooperCompanies (Nasdaq: COO) is a leading medical device company that operates through two business units, one being CooperSurgical. CooperSurgical’s core products fall under the category of fertility and women’s health.
Innovation in maternal health is critical. Although America has the highest maternal mortality rate among developed nations, 80% of pregnancy-related deaths are preventable with early intervention, monitoring, and specialized pregnancy services. The market size further promotes the development of pregnancy care and maternal monitoring solutions. The maternal health market size is expected to grow from $23.9B in 2023 to $72.6B by 2032 at a compound annual growth rate (CAGR) of 14.9% These growth projections are justified considering the recent legislative tailwinds bolstering maternal healthcare.
In September, the Biden-Harris administration invested $100M to expand access to maternal health care. By the end of 2023, over 17 states were in various stages of consideration, planning, or implementation of Medicaid doula reimbursement. We also saw exciting M&A activity in maternal and fetal monitoring (see ASV’s Blog about Nuvo Group merger here).
From an innovation perspective, we are also seeing a surge in early-stage maternal health startups, specifically maternal health monitoring solutions such as:
80BeatsMedical - Series A stage. 80 Beats Medical’s differentiated, non-invasive digital biomarkers quickly screens and diagnoses preeclampsia with greater accuracy and at a lower cost than current standard of care.
BloomLife - Series A stage. Bloomlife’s remote care platform combines unique prenatal wearables, connected devices and data analytics to improve access to care, enabling care teams to more easily and efficiently manage maternal and fetal health.
NovoCuff - Seed stage. NovoCuff is developing a novel device to address challenges associated with preterm birth.
Delfina Care - Series A stage. Delfina is a digital platform that connects patients and providers during pregnancy care. Patients are reassured knowing their providers are in the loop about their health and providers are offered a comprehensive data source to better understand their patients’ health in between visits.
RadiantOxymetry - Series A stage. Radiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth by monitoring fetal oxygenation during labor.
This acquisition proves appetite and emphasizes the growing need for innovation in this space. We are excited to watch it grow!
